Invitrogen has announced a partnership with RXi Pharmaceuticals in the field of RNAi (RNA interference) technologies, whereby RXi Pharmaceuticals will exclusively license RNAi products from Invitrogen for use in human therapeutic purposes.
Invitrogen Corp. (IVGN) reported third quarter net income of $30.99 million, compared to a loss of $129.79 million in the same quarter prior year. The company expects that earnings per share in the next quarter to grow at 3 to 4 times the rate of revenue.